Acalabrutinib (Acalabrutinib 100 mg) is a prescription cancer medicine taken by mouth. It is used to treat some blood cancers that start in B cells, a type of white blood cell. In adults, it is used for chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). Acalabrutinib (Acalabrutinib 100 mg) belongs to a group of medicines called Bruton tyrosine kinase (BTK) inhibitors. It blocks a signal that cancerous B cells need to grow and survive. Doctors may prescribe it alone or with other cancer medicines. It is usually taken twice a day and needs regular check-ups and blood tests.
Acalabrutinib (Acalabrutinib 100 mg) is a targeted cancer medicine. Standard chemotherapy damages many fast-growing cells in the body, but Acalabrutinib (Acalabrutinib 100 mg) works differently. It targets one protein called Bruton tyrosine kinase (BTK). B cells use BTK to pass on growth signals. In CLL, SLL and mantle cell lymphoma, cancerous B cells depend on these signals to multiply, move around the body and stay alive. When BTK is blocked, the cancer cells lose this support.
In adults, Acalabrutinib (Acalabrutinib 100 mg) is used for:
Acalabrutinib (Acalabrutinib 100 mg) is a tablet or capsule taken at home. How long you take Acalabrutinib (Acalabrutinib 100 mg) depends on your treatment plan. When it is used alone, or after combination treatment for mantle cell lymphoma, it is usually continued for as long as it keeps working and side effects stay manageable. When it is combined with venetoclax for CLL/SLL, treatment usually stops after a set number of 28-day cycles (up to 14 cycles). Your doctor will tell you how long to take it. When taken regularly twice a day, Acalabrutinib (Acalabrutinib 100 mg) keeps BTK almost fully blocked across each 12-hour dosing period.
Acalabrutinib (Acalabrutinib 100 mg) needs close medical supervision. It can cause serious infections, serious bleeding, low blood counts, heart rhythm problems and liver injury. Some of these can be life-threatening. People taking it have also developed new cancers, most often skin cancers. Your doctor will order regular blood tests and liver tests, check your skin, and ask about your symptoms at each visit.
Acalabrutinib (Acalabrutinib 100 mg) also interacts with many common medicines. Some of these can change how much of it stays in your blood. Always tell every doctor, dentist and pharmacist you see that you take Acalabrutinib (Acalabrutinib 100 mg). Your doctor may need to pause it before an operation or dental procedure because it raises the risk of bleeding.
Common Side Effects (Usually Mild)
Serious Side Effects (Seek Urgent Medical Attention)
B cells are white blood cells that help fight infection. Each B cell has a receptor on its surface that works like an "on" switch. When the switch is turned on, a chain of signals passes into the cell. One key link in that chain is an enzyme called Bruton tyrosine kinase (BTK). An enzyme is a protein that speeds up a chemical step inside the body.
In CLL, SLL and mantle cell lymphoma, cancerous B cells rely on BTK signals to multiply, travel through the body, and stick in places like the lymph nodes and bone marrow, where they are protected.
Acalabrutinib (Acalabrutinib 100 mg) fits into the working pocket of BTK. There it forms a strong, lasting chemical bond, called a covalent bond, with one part of the enzyme. Once this bond forms, that BTK molecule stops working. The liver also turns Acalabrutinib (Acalabrutinib 100 mg) into an active breakdown product, and this product blocks BTK in the same way.
With BTK switched off, growth and survival signals no longer reach the cancerous B cells properly. In laboratory studies, this stopped cancerous B cells from multiplying and slowed tumour growth.
The liver mainly breaks down Acalabrutinib (Acalabrutinib 100 mg) using an enzyme system called CYP3A. This is why medicines that speed up or slow down CYP3A can change how much Acalabrutinib (Acalabrutinib 100 mg) is in your blood.
Animal studies suggest Acalabrutinib (Acalabrutinib 100 mg) may harm an unborn baby and may cause dystocia, which means a difficult or blocked labour. Your doctor may advise a pregnancy test before you start treatment if you can become pregnant. If you can become pregnant, use effective contraception during treatment and for 1 week after the last dose. Tell your doctor right away if you become pregnant or think you may be pregnant.
Do not breastfeed while taking Acalabrutinib (Acalabrutinib 100 mg) or for 2 weeks after the last dose. The medicine passed into breast milk in animal studies and could harm a breastfed baby.
Some people feel tired or dizzy while taking Acalabrutinib (Acalabrutinib 100 mg). Do not drive or use machines if you feel tired, dizzy or faint.
No dose change is needed for mild to moderate kidney problems. The effect of severe kidney disease or dialysis on this medicine has not been studied. Tell your doctor about any kidney problems.
People with severe liver disease should avoid Acalabrutinib (Acalabrutinib 100 mg). It can also cause liver injury in anyone. Your doctor will check your liver function before and during treatment. Tell your doctor if you have ever had liver disease or hepatitis B.
Acalabrutinib (Acalabrutinib 100 mg) can cause liver injury and serious bleeding. Ask your doctor whether you should limit or avoid alcohol during treatment.
Acalabrutinib (Acalabrutinib 100 mg) has not been shown to be safe and effective in children. It is used in adults only.
In studies, people aged 65 and over had serious side effects more often than younger people. The medicine worked equally well in both groups. Older adults need careful monitoring.
If you or someone else has taken more Acalabrutinib (Acalabrutinib 100 mg) than prescribed, contact a doctor or go to the nearest emergency department straight away. Take the medicine pack with you. An overdose may raise the risk of the medicine's known serious effects, such as bleeding, heart rhythm problems and liver injury. Watch for unusual bleeding or bruising, a fast or irregular heartbeat, dizziness, fainting, or yellowing of the skin. Hospital staff will monitor the person and treat any symptoms.
Seek medical help right away if you notice:
Therapeutic Class
Anticancer (antineoplastic) medicine
Action Class
Bruton tyrosine kinase (BTK) inhibitor (kinase inhibitor)
Chemical Class
Imidazopyrazine derivative
Habit Forming
No
Checkout Editorial Policy
Top Selling Medicines
Top Health Products
Top Selling Devices